The recently approved anti-inflammatory plaque psoriasis drug Siliq (brodalumab) will hit the market later this year facing major hurdles, including a black box warning, restrictive prescribing protocols, and steep competition. The development of Siliq came out of a partnership between Amgen and AstraZeneca. In 2015, Amgen backed out of the deal after observing suicidal ideation in patients who were treated with the drug during clinical trials. Amgen feared the drug would not only have a difficult road to approval due to the suicide risk, if it were approved, it would come with restrictive labeling. AstraZeneca then struck a deal with ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.